A 27-year-old New York City woman died following an intravenous NAD⁺ infusion administered by an unlicensed practitioner at an unregulated wellness clinic. The death highlights the distinction between evidence-supported NAD⁺ research—which shows promise in animal models but remains unconvincing in human studies—and the proliferation of unproven intravenous formulations marketed without scientific validation or medical oversight.
Key Points
- NAD⁺ IV infusions lack rigorous human safety and efficacy data despite popularity
- Unlicensed practitioners and unregulated clinics amplify risks of contamination, dosing errors
- Animal research on NAD⁺ precursors (NR, NMN) does not translate reliably to human lifespan extension
Longevity Analysis
This fatality underscores a critical vulnerability in longevity medicine: the gap between preliminary animal research and validated human protocols creates an opportunity for exploitation by practitioners operating outside regulatory frameworks. NAD⁺ research has identified genuine biological relevance—the molecule's role in energy metabolism and DNA repair mechanisms—but the translation from controlled laboratory conditions to commercial infusions represents a substantial and poorly managed risk. The quality, sterility, concentration, and purity of intravenous NAD⁺ preparations exist outside any standardized manufacturing or regulatory oversight. When combined with administration by unlicensed individuals, even a theoretically sound intervention becomes a vector for contamination, dosing errors, and adverse reactions that cannot be managed appropriately. The field requires a return to disciplined evaluation: isolating interference (unregulated practitioners, unvalidated protocols), ac
Original published by LifeSpan.io, by Arkadi Mazin.